Use of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasu's arteritis.
Kaitlin A QuinnHugh D AlessiCristina PonteEmily RoseMark A AhlmanChristopher RedmondYiming LuoErtugrul Cagri BolekCarol A LangfordPeter A MerkelPeter C GraysonPublished in: Rheumatology (Oxford, England) (2022)
Incorporation of FDG-PET data into assessment of TAK influences decisions about enrolment of patients into trials, improves physician confidence about clinical assessment and could help reduce variability in study populations. Future trials in TAK should consider incorporating FDG-PET data into eligibility criteria.
Keyphrases
- positron emission tomography
- computed tomography
- pet ct
- pet imaging
- clinical trial
- end stage renal disease
- electronic health record
- ejection fraction
- newly diagnosed
- emergency department
- big data
- prognostic factors
- health insurance
- open label
- study protocol
- current status
- double blind
- patient reported
- genetic diversity
- placebo controlled